Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BLCO Bausch + Lomb	$14.06 -1.3%	$12.59	$10.45 ▼ $21.69	$5.04B	0.62	747,834 shs	1.02 million shs
SNN Smith & Nephew SNATS	$31.48 -1.1%	$29.70	$23.69 ▼ $31.84	$13.95B	0.69	1.08 million shs	715,792 shs
SOLV Solventum	$73.97 -0.6%	$74.22	$54.26 ▼ $85.92	$12.87B	0.55	674,936 shs	449,118 shs
ZBH Zimmer Biomet	$96.85 -0.5%	$93.19	$89.22 ▼ $116.71	$19.26B	0.71	1.93 million shs	1.23 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BLCO Bausch + Lomb	-0.41%	+2.16%	+18.75%	+2.56%	-16.29%
SNN Smith & Nephew SNATS	+2.90%	+7.63%	+9.14%	+17.90%	+11.61%
SOLV Solventum	+2.04%	+1.96%	+1.66%	+10.23%	+31.41%
ZBH Zimmer Biomet	+0.69%	+3.33%	+6.36%	-4.11%	-11.52%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BLCO Bausch + Lomb	2.1922 of 5 stars	2.1	2.0	0.0	0.0	2.0	1.7	2.5
SNN Smith & Nephew SNATS	2.8297 of 5 stars	1.0	3.0	2.5	0.0	2.9	0.0	3.8
SOLV Solventum	1.4918 of 5 stars	2.1	2.0	0.0	0.0	3.4	0.0	1.3
ZBH Zimmer Biomet	4.9119 of 5 stars	3.2	5.0	1.7	3.7	2.6	2.5	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BLCO Bausch + Lomb	2.17	Hold	$15.45	9.96% Upside
SNN Smith & Nephew SNATS	2.00	Hold	$28.00	-11.05% Downside
SOLV Solventum	2.27	Hold	$84.38	14.07% Upside
ZBH Zimmer Biomet	2.35	Hold	$111.39	15.01% Upside

Current Analyst Ratings Breakdown

Latest BLCO, ZBH, SNN, and SOLV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/15/2025	SOLV Solventum	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$80.00 ➝ $103.00
7/15/2025	ZBH Zimmer Biomet	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$135.00
7/9/2025	BLCO Bausch + Lomb	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$13.00 ➝ $15.00
7/8/2025	BLCO Bausch + Lomb	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$15.50 ➝ $16.00
7/8/2025	ZBH Zimmer Biomet	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	In-Line ➝ In-Line	$102.00 ➝ $96.00
7/1/2025	SOLV Solventum	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$90.00
6/9/2025	BLCO Bausch + Lomb	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$19.00 ➝ $16.00
6/6/2025	SOLV Solventum	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Weight
5/19/2025	SOLV Solventum	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$78.00 ➝ $87.00
5/12/2025	ZBH Zimmer Biomet	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$115.00 ➝ $101.00
5/9/2025	SOLV Solventum	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$80.00 ➝ $78.00

(Data available from 7/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BLCO Bausch + Lomb	$4.79B	1.04	$1.85 per share	7.60	$18.57 per share	0.76
SNN Smith & Nephew SNATS	$5.81B	2.37	$3.12 per share	10.09	$12.04 per share	2.61
SOLV Solventum	$8.25B	1.55	$9.88 per share	7.49	$17.13 per share	4.32
ZBH Zimmer Biomet	$7.68B	2.50	$13.12 per share	7.38	$62.67 per share	1.55

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BLCO Bausch + Lomb	-$317M	-$1.03	N/A	14.64	1.60	-7.50%	2.62%	1.28%	7/30/2025 (Estimated)
SNN Smith & Nephew SNATS	$412M	$2.16	14.57	15.74	0.97	N/A	N/A	N/A	8/5/2025 (Estimated)
SOLV Solventum	$478M	$2.16	34.24	13.47	1.91	4.55%	31.01%	6.53%	8/7/2025 (Estimated)
ZBH Zimmer Biomet	$903.70M	$4.52	21.43	10.92	2.27	11.86%	12.73%	7.34%	8/7/2025 (Estimated)

Latest BLCO, ZBH, SNN, and SOLV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	SOLV Solventum	$1.45	N/A	N/A	N/A	$2.12 billion	N/A
8/7/2025	Q2 2025	ZBH Zimmer Biomet	$1.99	N/A	N/A	N/A	$2.06 billion	N/A
7/30/2025	Q2 2025	BLCO Bausch + Lomb	$0.07	N/A	N/A	N/A	$1.25 billion	N/A
5/8/2025	Q1 2025	SOLV Solventum	$1.19	$1.34	+$0.15	$0.78	$2.02 billion	$2.07 billion
5/5/2025	Q1 2025	ZBH Zimmer Biomet	$1.77	$1.81	+$0.04	$0.91	$1.89 billion	$1.91 billion
4/30/2025	Q1 2025	BLCO Bausch + Lomb	$0.03	-$0.07	-$0.10	-$0.60	$1.15 billion	$1.15 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BLCO Bausch + Lomb	N/A	N/A	N/A	N/A	N/A
SNN Smith & Nephew SNATS	$0.89	2.83%	N/A	41.20%	N/A
SOLV Solventum	N/A	N/A	N/A	N/A	N/A
ZBH Zimmer Biomet	$0.96	0.99%	N/A	21.24%	N/A

Latest BLCO, ZBH, SNN, and SOLV Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/30/2025	ZBH Zimmer Biomet	quarterly	$0.24	1.03%	6/26/2025	6/26/2025	7/31/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BLCO Bausch + Lomb	0.74	1.56	0.96
SNN Smith & Nephew SNATS	0.62	2.89	1.33
SOLV Solventum	2.40	1.19	0.85
ZBH Zimmer Biomet	0.53	2.44	1.46

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BLCO Bausch + Lomb	11.07%
SNN Smith & Nephew SNATS	25.64%
SOLV Solventum	N/A
ZBH Zimmer Biomet	88.89%

Insider Ownership

Company	Insider Ownership
BLCO Bausch + Lomb	0.76%
SNN Smith & Nephew SNATS	1.00%
SOLV Solventum	0.05%
ZBH Zimmer Biomet	1.39%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BLCO Bausch + Lomb	13,500	353.80 million	351.12 million	Optionable
SNN Smith & Nephew SNATS	17,349	437.98 million	433.60 million	Optionable
SOLV Solventum	22,000	173.01 million	172.93 million	Optionable
ZBH Zimmer Biomet	17,000	197.85 million	195.10 million	Optionable

BLCO, ZBH, SNN, and SOLV Headlines

Recent News About These Companies

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Given Average Recommendation of "Hold" by Brokerages

July 24 at 4:37 AM | marketbeat.com

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Position Raised by Auto Owners Insurance Co

July 23 at 7:40 AM | marketbeat.com

Zimmer Biomet Q2 Preview: Combining Monogram Autonomous Robotics With ROSA

July 21 at 1:16 PM | seekingalpha.com

Zimmer Biomet (NYSE:ZBH) and Resonate Blends (OTCMKTS:KOAN) Head to Head Comparison

July 21 at 2:20 AM | americanbankingnews.com

SMH physicians use hand-held robots for knee replacement surgeries

July 20, 2025 | msn.com

AMG National Trust Bank Increases Stock Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

July 19, 2025 | marketbeat.com

Zimmer Biomet to pay $177M for orthopedic robotics company

July 18, 2025 | beckershospitalreview.comB

Cerity Partners LLC Cuts Stock Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

July 18, 2025 | marketbeat.com

Zimmer Biomet (NYSE:ZBH) Upgraded at Roth Capital

July 18, 2025 | americanbankingnews.com

ZBH Stock Set to Benefit From New Monogram Technologies Buyout Deal

July 17, 2025 | zacks.com

Roth MKM upgrades Zimmer Biomet Holdings (ZBH) to a Buy

July 17, 2025 | theglobeandmail.com

What You Need To Know Ahead of Zimmer Biomet's Earnings Release

July 17, 2025 | msn.com

MONOGRAM TECHNOLOGIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Monogram Technologies Inc. - MGRM

July 16, 2025 | businesswire.com

Needham Maintains a Neutral Stance on Zimmer Biomet Holdings (ZBH)

July 16, 2025 | insidermonkey.com

Equity Investment Corp Acquires 17,286 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

July 16, 2025 | marketbeat.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Sarepta Therapeutics (SRPT), Zimmer Biomet Holdings (ZBH) and Eli Lilly & Co (LLY)

July 16, 2025 | theglobeandmail.com

New York State Common Retirement Fund Grows Stock Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

July 16, 2025 | marketbeat.com

Zimmer Biomet enters agreement to acquire orthopaedic robotics company, Monogram Technologies

July 15, 2025 | pharmabiz.comP

Zimmer Biomet inks $177M deal for Monogram and its hands-free orthopedic robot

July 15, 2025 | fiercebiotech.comF

Zimmer Biomet wins price target raise at Roth

July 15, 2025 | cantechletter.comC

Zimmer upgraded to Buy at Roth Capital on Monogram deal

July 15, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLCO, ZBH, SNN, and SOLV Company Descriptions

Bausch + Lomb NYSE:BLCO

$14.06 -0.19 (-1.30%)

Closing price 03:59 PM Eastern

Extended Trading

$14.17 +0.12 (+0.82%)

As of 05:31 PM Eastern

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.

Smith & Nephew SNATS NYSE:SNN

$31.48 -0.36 (-1.13%)

Closing price 03:59 PM Eastern

Extended Trading

$31.48 +0.01 (+0.02%)

As of 07:25 PM Eastern

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT. The Advanced Wound Management segment includes advanced wound care, advanced wound bioactives, and advanced wound devices businesses. The company was founded in 1856 and is headquartered in Watford, the United Kingdom.

Solventum NYSE:SOLV

$73.97 -0.43 (-0.58%)

Closing price 03:59 PM Eastern

Extended Trading

$73.75 -0.22 (-0.29%)

As of 07:23 PM Eastern

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes. The Dental Solutions segment provides a comprehensive suite of dental and orthodontic products including brackets, aligners, restorative cements, and bonding agents. The Health Information Systems provides software solutions including computer-assisted, physician documentation, direct-to-bill and coding automation, classification methodologies, speech, recognition, and data visualization platforms. The Purification and Filtration segment provides purification and filtration technologies including filters, purifiers, cartridges, and membranes. The company was incorporated in 2023 and is based in Saint Paul, Minnesota.

Zimmer Biomet NYSE:ZBH

$96.85 -0.48 (-0.49%)

Closing price 03:59 PM Eastern

Extended Trading

$96.82 -0.03 (-0.03%)

As of 05:28 PM Eastern

Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers robotic, surgical, and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time